News for Healthier Living

Once-Weekly Oral Islatravir Plus Lenacapavir Maintains High Rates of Virologic Suppression in Adults with HIV

A phase 2 randomized study evaluating the efficacy and safety of once-weekly oral islatravir plus lenacapavir (ISL+LEN) in virologically suppressed adults with HIV found that ISL+LEN maintained high rates of virologic suppression through 48 weeks, with no treatment-related grade 3 or greater adverse events or serious adverse events.

December 22, 2025


December 22 2025

December 21 2025

December 20 2025

December 19 2025

December 18 2025

December 17 2025

December 16 2025

December 15 2025

December 14 2025

December 13 2025

December 12 2025

December 11 2025

December 10 2025

December 9 2025

December 8 2025